학술논문
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
Document Type
article
Author
Sweeney, Daniel A; Tuyishimire, Bonifride; Ahuja, Neera; Beigel, John H; Beresnev, Tatiana; Cantos, Valeria D; Castro, Jose G; Cohen, Stuart H; Cross, Kaitlyn; Dodd, Lori E; Erdmann, Nathan; Fung, Monica; Ghazaryan, Varduhi; George, Sarah L; Grimes, Kevin A; Hynes, Noreen A; Julian, Kathleen G; Kandiah, Sheetal; Kim, Hannah Jang; Levine, Corri B; Lindholm, David A; Lye, David C; Maves, Ryan C; Oh, Myoung-Don; Paules, Catharine; Rapaka, Rekha R; Short, Willam R; Tomashek, Kay M; Wolfe, Cameron R; Kalil, Andre C
Source
Open Forum Infectious Diseases. 10(5)
Subject
Language
Abstract
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019.